Journal
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
Volume 39, Issue 9, Pages 1339-1349Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10803-009-0750-3
Keywords
ASD; Medication; Psychotropic medication; Non-psychotropic medication
Categories
Funding
- NIA NIH HHS [R01 AG008768-14, R01 AG008768-12, R01 AG08768, R01 AG008768-13, R01 AG008768-17, R01 AG008768, R01 AG008768-11, R01 AG008768-18, R01 AG008768-10, R01 AG008768-15, R01 AG008768-16] Funding Source: Medline
- NICHD NIH HHS [P30 HD003352-43, P30 HD03352, P30 HD003352-43S2, P30 HD003352-429019, P30 HD003352-39, P30 HD003352-40, P30 HD003352-439019, P30 HD003352-429018, P30 HD003352-41, P30 HD003352-38, P30 HD003352-429016, P30 HD003352-429017, P30 HD003352-429015, P30 HD003352-43S1, P30 HD003352-37, P30 HD003352-35, P30 HD003352-42, P30 HD003352] Funding Source: Medline
Ask authors/readers for more resources
Medication use was examined in 286 adolescents and adults with ASD over a 4.5 year period. A total of 70% were taking a psychotropic or non-psychotropic medication at the beginning of the study. Both the number of psychotropic and non-psychotropic medications taken, and the proportion of individuals taking these medications, increased significantly over the study period, with 81% taking at least one medication 4.5 years later. Our findings suggested a high likelihood of staying medicated over time. Thus, adolescents and adults with ASD are a highly and increasingly medicated population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
